corp_html/news/19.html

<p align="center"><b>PLIVA Krakow Zakladi Farmaceutyczne S.A, a subsidiary of 
  PLIVA d. d. Zagreb, applied for price approval for the product Virlix® 10mg*20tab. 
  (cetirizine)</b></p>
<p>PLIVA Krakow has applied for price approval of the drug Virlix® 10mg*20tab. 
  (cetirizine) which will replace the product Zyrtec® 10mg*20tab. (cetirizine) 
  in PLIVA Krakows product portfolio.</p>
<p>Both drugs are licensed products of UCB, and while UCB will take over the sales 
  of Zyrtec® 10mg*20tab., PLIVA Krakow will market cetirizine under the trademark</p>
<p>Virlix® 10mg*20tab. Virlix® 10mg*20tab. has already been registered, listed 
  on the reimbursement list and is expected to be launched soon on the Polish 
  market.</p>
<p>In addition to cetirizine, PLIVA and UCB have earlier signed collaboration 
  agreements for the products Mistabron® amp. 600 mg (mesna, a respiratory drug) 
  and Nootropil® 400 mg (piracetam, nootropic). </p>
1	dpavlin	1.1	<p align="center"><b>PLIVA Krakow Zakladi Farmaceutyczne S.A, a subsidiary of
2			PLIVA d. d. Zagreb, applied for price approval for the product Virlix® 10mg*20tab.
3			(cetirizine)</b></p>
4			<p>PLIVA Krakow has applied for price approval of the drug Virlix® 10mg*20tab.
5			(cetirizine) which will replace the product Zyrtec® 10mg*20tab. (cetirizine)
6			in PLIVA Krakows product portfolio.</p>
7			<p>Both drugs are licensed products of UCB, and while UCB will take over the sales
8			of Zyrtec® 10mg*20tab., PLIVA Krakow will market cetirizine under the trademark</p>
9			<p>Virlix® 10mg20tab. Virlix® 10mg20tab. has already been registered, listed
10			on the reimbursement list and is expected to be launched soon on the Polish
11			market.</p>
12			<p>In addition to cetirizine, PLIVA and UCB have earlier signed collaboration
13			agreements for the products Mistabron® amp. 600 mg (mesna, a respiratory drug)
14			and Nootropil® 400 mg (piracetam, nootropic). </p>